Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients.

Blood Cancer J · 2026 · PMC13039453 · PMID 41916955

Europe PMC DOI

hedged sentence

0.0740

closest p · 1.5× alpha

0.0740

boldest claim

The sentences

showed a trendp = 0.074so close (0.05 < p ≤ 0.1)

Primary prophylactic IVIG use showed a trend toward lower CMV reactivation ( p = 0.074).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.